Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

AIMS: In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Murphy, Sabina A., Antman, Elliott M., Wiviott, Stephen D., Weerakkody, Govinda, Morocutti, Giorgio, Huber, Kurt, Lopez-Sendon, Jose, McCabe, Carolyn H., Braunwald, Eugene
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2008
Soggetti:
Clinical Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2567025/
https://ncbi.nlm.nih.gov/pubmed/18682445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehn362
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi